- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Merck & Company Inc (MRK)
152.77
+2.11(+1.40%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
150.66
153.75
52 wk Range
77.58
154.49
MRK Comments
Compiled here, all relevant comments and discussions regarding the MRK stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
How about IMRX?
Hi
MRK is nearing the end of a bullish accumulation phase; it is worth buying this week between $114 and $115, with resistance expected in the second week of July between $134 and $136, representing a potential gain of 20%.
AFS FUND - PORTFOLIO OF US PHARMACEUTICAL INDUSTRY STOCKS: YOU WILL ALSO BE PROTECTED FROM DEVALUATION AND CURRENCY FLUCTUATIONS.
The Trump administration will inject $233 billion into the US pharmaceutical manufacturing sector... Pharmaceutical companies are investing in the US to avoid tariffs. Following Trump's tariff threats on pharmaceuticals, major pharmaceutical companies such as Merck, AstraZeneca, and Johnson & Johnson announced investments. Merck announced a $1 billion investment in a facility in Delaware at the end of April, while UK-based pharmaceutical company AstraZeneca announced in July that it planned to invest $50 billion in the US for pharmaceutical manufacturing and R&D. Johnson & Johnson also announced in March that it would increase its investment in the US to over $55 billion within the next four years. Swiss-based Roche also announced that it would invest $50 billion in pharmaceuticals and diagnostics in the US within the next five years. Eli Lilly announced earlier this week that it plans to build a new $6.5 billion manufacturing facility in Texas. The Trump administration wants to bring pharmaceutical manufacturing back to the US.
Why did this drop tho??
Speculation
what happened to the average volume Investing.com?
Pipeline is promising but still in the future.
Currently a real buying opportunity.
toldya
This is it, a 5-year-low. Keep buying the bottom folks.
dang. many bag holders including me 500 shares.
This stock is garbage
I started buying.
Now is the time to buy. Not after it goes up again.
Finally some momentum. Next stop $100
$76.89 (-9%)
The fair value of Merck & Company Inc (MRK) is $138.08. The current price ($83.36) indicates stock is undervalued by 65.64%. The Suggested Sell Price is $179.5.
here you find value
Investing.com is now saying the stock should be valued as $112. Why the sudden changed from $56.93?
good buy with call, good luck
Company Health is rated as GREAT. Analysts say the price should be around $102.71. But Investing.com is saying that the price should be around $56.93????? What are they using a Dart Board to come up with these prices?
Will it go up or continue to fall.. what is the best price to buy?
How come MRK can go up under Trump's totally adverse EO to force 80% price reduction?
How come MRK can go up under Trump's totally adverse EO to force 80% price reduction?
How come MRK can go up under Trump's totally adverse EO to force 80% price reduction?
How come MRK can go up under Trump's totally adverse EO to force 80% price reduction?
News is yhat MRK has good stuff in their pipeline.
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.